Media, page-88

I remember that many HC posters were outraged when VLA’s board supported the takeover by Merck for $500m (or $1.70 a share which was also a 170% premium). But obviously it was unanimously approved by shareholders i.e the magical 90% mark.

my point is that I think you’d see the scenario here if there was a similar scenario. We’d be disappointed that it wasn’t more - but I don’t think many people would turn down almost tripling their money overnight

The biggest premium over the past five years for a biotech takeover was the 290% premium sanofi paid for synthorx

No one can forget of course Gilead’s $US21 billion takeover of immunomedics end of last year